-
-
-
-
-
-
-
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
-
-
-
-
-
-
-
Harrow to Acquire Melt Pharmaceuticals
-
-
-
-
-
-
-
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States
-
-
-
-
-
-
-
Harrow Health (HROW) Announces Transitional Pass-Through Reimbursement Status for TRIESENCE 40 mg/mL
-
-
-
-
-
-
-
Harrow Appoints Amir H. Shojaei as Chief Scientific Officer
-
-
-
-
-
-
-
Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products
-
-
-
-
-
-
-
Harrow Health (HROW) Provides TRIESENCE Relaunch Update
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

